Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
100%(3 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
2
40%
Ph phase_4
2
40%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 4Post-market surveillance
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 42 (40.0%)

Trials by Status

withdrawn120%
active_not_recruiting120%
completed360%

Recent Activity

1 active trials
Showing 5 of 5
withdrawnphase_4

A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

NCT05494593
active_not_recruitingphase_2

Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment

NCT06031259
completedphase_1

An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

NCT01506141
completedphase_2

Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094

NCT02412787
completedphase_4

A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

NCT05058391

Clinical Trials (5)

Showing 5 of 5 trials
NCT05494593Phase 4

A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Withdrawn
NCT06031259Phase 2

Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment

Active Not Recruiting
NCT01506141Phase 1

An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

Completed
NCT02412787Phase 2

Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094

Completed
NCT05058391Phase 4

A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5